Keep pulling the thread on Jenny Rook.
Blackstone is investing $250 million in the biotech startup Anagram Therapeutics.
Blackstone's latest Life Sciences Fund has raised $6.3 billion in commitments, the firm's largest amount ever for backing clinical trials.
Roche has acquired PathAI, a company focused on applying AI to healthcare.
Blackstone's investment in Anagram Therapeutics is part of its broader strategy to acquire more cutting-edge drug-making companies.
Blackstone Life Sciences has approximately $17 billion in assets under management (AUM).
Blackstone Life Sciences typically invests in late-stage medicines in exchange for royalties on future sales.
Genoa Ventures' strategy is to lead the first institutional funding rounds for its portfolio companies.
Genoa Ventures invests in early-stage companies with the expectation that they will become public in a 7 to 10-year timeframe.
Proteomics company Alamar Bio completed an oversubscribed IPO on the Nasdaq and its stock has traded up in the months following the offering.
Alamar Bio's technology enables the measurement of more proteins in patient samples with greater precision and sensitivity than previously possible.
PathAI's solutions include data generation from samples, data visualization, AI-powered analysis tools, and workflow improvements for healthcare systems.
The UK Biobank is a rich dataset containing extensive longitudinal information about patients and their healthcare.